首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Expert Review Of Anticancer Therapy

Expert Review Of Anticancer Therapy杂志,由Taylor and Francis Ltd.出版,于2001年创刊,Bimonthly,出版语言English,ISSN:1473-7140,E-ISSN:1744-8328。

投稿咨询
Expert Review Of Anticancer Therapy
Expert Review Of Anticancer Therapy
Expert Review Of Anticancer Therapy
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
3区
影响因子
3
CiteScore
4.9
期刊收录
SCI、SCIE

Expert Review Of Anticancer Therapy(中文译名:《抗癌治疗专家评论》),ISSN:1473-7140,EISSN:1744-8328,是Taylor and Francis Ltd.出版的国际性学术期刊,创刊于2001年,以Bimonthly形式稳定发行,2026年总发文量约164篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3,2025年期刊CiteScore为4.9,2025年期刊自引率约3.3%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Expert Review Of Anticancer Therapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、GERMANY (FED REP GER)、France、England、Canada、Belgium等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMUNICANCER、HARVARD UNIVERSITY、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、MEMORIAL SLOAN KETTERING CANCER CENTER、FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI MILAN、ROYAL MARSDEN NHS FOUNDATION TRUST等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 172 / 333

48.5

学科:ONCOLOGY SCIE Q3 242 / 333

27.48

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 160 / 328

51.4

学科:ONCOLOGY SCIE Q3 209 / 328

36.43


中国学者近期发文

1
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM score

Author:Sherazi, Abdul Wasay; Rasool, Muhammad Fawad; Jiao, Zheng; Alqahtani, Faleh

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2657916

2
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysi

Author:Ji, Jianwei; Li, Taoying; Li, Zhanwu; Zhou, Jianhua; Qin, Fuhong; Teng, Mengmeng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2628946

3
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy consideration

Author:Lin, Shen; Wang, Xiangzhen; Yang, Lijing; Luo, Shaohong; Huang, Xiaoting; Weng, Xiuhua; Xu, Xiongwei

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2630025

4
Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenge

Author:Lim, Jeong Uk; Oya, Yuko; Fu, Rui; Sooi, Kenneth; Ang, Yvonne L. E.; Soo, Ross A

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2630026

5
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based stud

Author:Jin, Qiu; Zhu, Yehang; He, Zhaopeng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2612042

6
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCL

Author:Huo, Gengwei; Chen, Peng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2026.2614708

7
Accuracy of high b-value diffusion-weighted imaging in identifying benign and malignant breast lesions: a systematic review and meta-analysi

Author:Zhang, Jupeng; Wu, Qi; Zhu, Xiqi; Li, Baosheng

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2510532

8
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphom

Author:Lin, Yaobin; Shi, Shenghong; Wu, Jiahui; Liu, Shan

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2517280

9
Epidemiologic and survival analysis for patients with secondary esophageal Cancer: a population-based study and external validatio

Author:Wang, Jie; Zha, Jingyun; Dong, Xiaoliang; Liu, Ping

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2517883

10
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicator

Author:Li, Yucong; Mi, Xuguang; Li, Xiaonan; Li, Xiao-Nan; Yang, Ying; Zhou, Ying; Jiang, Xianzhuo; Yu, Yingying; Ni, Zhiqiang; Zhang, Junzi; Lin, Xiuying; Fang, Yanqiu; Hou, Junjie

Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2025.2522251


在线咨询

Expert Review Of Anticancer Therapy

国际简称:EXPERT REV ANTICANC参考译名:抗癌治疗专家评论

年发文量:164 CiteScore:4.9 是否预警:否 Gold OA文章占比:2.11% 研究类文章占比:28.66%

杂志社联系方式:EXPERT REVIEWS, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Expert Review Of Anticancer Therapy